subscribeSubscribe
Court Blocks Norwich`s ANDA Approval Until 2029

Court Blocks Norwich`s ANDA Approval Until 2029
ACCESSWIRE
11 Apr 2024
Share Share
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals

Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
ACCESSWIRE
05 Apr 2024
Share Share
Bausch notches win in Xifaxan case against Alvogen

Bausch notches win in Xifaxan case against Alvogen
Zoey Becker FIERCE PHARMA
03 Nov 2023
Share Share
Salix to Present Data from XIFAXAN(R) (Rifaximin) Clinical Research at EASL`s ™

Salix to Present Data from XIFAXAN(R) (Rifaximin) Clinical Research at EASL`s ™
ACCESSWIRE
19 Jun 2023
Share Share
Norwich`s Generic Rifaximin Receives Approval in the U.S.

Norwich`s Generic Rifaximin Receives Approval in the U.S.
FDA
02 Jun 2023
Share Share
U.S. District Court Upholds Final Judgment for XIFAXAN® 550 mg

U.S. District Court Upholds Final Judgment for XIFAXAN® 550 mg
PRESS RELEASE
17 May 2023
Share Share
Salix Will Present Rifaximin Data at AASLD`s The Liver Meeting(R) 2022

Salix Will Present Rifaximin Data at AASLD`s The Liver Meeting(R) 2022
ACCESSWIRE
04 Nov 2022
Share Share
Salix Will Present XIFAXAN(R, TRULANCE and RELISTOR Data at Scientific Meeting

Salix Will Present XIFAXAN(R, TRULANCE and RELISTOR Data at Scientific Meeting
ACCESSWIRE
24 Oct 2022
Share Share
Bausch Health Responds to Norwich Tentative FDA Approval for a 200 mg Rifaximin

Bausch Health Responds to Norwich Tentative FDA Approval for a 200 mg Rifaximin
PRNEWSWIRE
09 Sep 2022
Share Share
Norwich`s Generic Rifaximin Receives Approval in the U.S.

Norwich`s Generic Rifaximin Receives Approval in the U.S.
FDA
02 Sep 2022
Share Share